Reduxin - Instructions For Use, Reviews, Price, Capsules 15 Mg And 10 Mg

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Reduksin

Reduksin: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Drug interactions
10. 10. Analogs
11. 11. Terms and conditions of storage
12. 12. Terms of dispensing from pharmacies
13. 13. Reviews
14. 14. Price in pharmacies

Latin name: Reduxin

ATX code: A08A

Active ingredient: sibutramine + microcrystalline cellulose (sibutramine + cellulose microcristallic)

Producer: OOO Ozon (Russia), Moscow Endocrine Plant (Russia)

Description and photo update: 2019-14-08

Prices in pharmacies: from 1108 rubles.

Buy

Reduxin is a centrally acting drug for the treatment of obesity.

Release form and composition

Reduksin dosage form - capsules: size No. 2, blue or blue; content - white or white-yellowish powder (10 pcs. in blisters, 3 or 6 packs in a cardboard box).

Active ingredients and their content:

• Blue capsules: sibutramine hydrochloride monohydrate - 10 mg, microcrystalline cellulose - 158.5 mg;
• Blue capsules: sibutramine hydrochloride monohydrate - 15 mg, microcrystalline cellulose - 153.5 mg.

Auxiliary component: calcium stearate.

The composition of the capsule shell: gelatin, titanium dioxide, patented blue dye, azorubin dye (10 mg capsules).

Pharmacological properties

Pharmacodynamics

Sibutramine belongs to prodrugs, its action is due to metabolites (primary and secondary amines). The latter are inhibitors of the reuptake of monoamines (dopamine, norepinephrine and serotonin). An increase in the level of neurotransmitters in synapses promotes an increase in the activity of central adrenergic and 5HT-serotonin receptors, which provides an increase in the feeling of satiety and a decrease in the need for food, as well as an intensification of thermal production.

Sibutramine indirectly activates beta3-adrenergic receptors by acting on brown adipose tissue. The decrease in body weight is accompanied by an increase in the concentration of high-density lipoproteins in the blood plasma and a decrease in the content of uric acid, triglycerides, low-density lipoproteins and total cholesterol. Sibutramine and its metabolites do not affect the release of monoamines and do not belong to monoamine oxidase inhibitors, and are also characterized by low affinity for a large number of neurotransmitter receptors, including glutamate (NMDA), serotonin (5-HT _2C, 5-HT ₁, 5-H _1B, 5HT _1A), benzodiazepine, adrenergic (alpha ₁, alpha ₂, beta ₁, beta₂, beta ₃), histamine (H ₁), dopamine (D ₁, D ₂) and muscarinic receptors.

Microcrystalline cellulose is an enterosorbent, has sorption properties and has a non-selective detoxification effect. It binds and removes from the body a variety of microorganisms, waste products, xenobiotics, allergens, toxins of endogenous and exogenous origin, as well as an excess of certain metabolites and metabolic products that provoke the development of endogenous toxicosis.

Pharmacokinetics

After oral administration, Reduxin is rapidly absorbed from the gastrointestinal tract by at least 77%. Sibutramine is characterized by the effect of "primary passage" through the liver, where it participates in biotransformation processes with the participation of the isoenzyme CYP3A4. In this case, two active metabolites are formed: monodesmethylsibutramine (M1) and didesmethylsibutramine (M2). After a single dose of 15 mg, the maximum level of M1 in the blood plasma is 4 ng / ml (range of values 3.2-4.8 ng / ml), and M2 - 6.4 ng / ml (range of values 5.6-7, 2 ng / ml). The maximum concentration of sibutramine in plasma is reached after 1.2 hours, and its metabolites M1 and M2 - after 3-4 hours.

When Reduxin is taken with food, the maximum concentration of metabolites decreases by 30%, and the time to reach it is increased by 3 hours, and the area under the concentration-time curve does not change. The active components of the drug are quickly distributed throughout the tissues. Sibutramine binds to plasma proteins by 97%, and its metabolites M1 and M2 by 94%. The equilibrium concentration of metabolites with pharmacological activity is reached within 4 days after the start of treatment and is approximately 2 times higher than the concentration in blood plasma after a single dose of a therapeutic dose. The half-life of sibutramine is 1.1 hours, the M1 metabolite is 14 hours, the M2 metabolite is 16 hours. Active metabolites are involved in hydroxylation and conjugation processes, forming inactive metabolites, which are excreted mainly in the urine.

The limited research results to date do not support the existence of clinically significant differences in the pharmacokinetics of the drug in male and female patients.

Pharmacokinetics in healthy elderly people (mean age 70 years) is identical to that in young volunteers.

Renal failure does not affect the AUC of the active metabolites M1 and M2, with the exception of the M2 metabolite in patients with end-stage renal failure undergoing dialysis.

In patients with moderate hepatic insufficiency after a single dose of Reduxin, the AUC of active metabolites M1 and M2 is 24% higher than in healthy volunteers.

Indications for use

According to the instructions, Reduxin is a drug used to reduce body weight:

• Alimentary obesity in patients with a body mass index (BMI) of 30 kg / m ²;
• Alimentary obesity in patients with a BMI of 27 kg / m ² in the presence of other risk factors due to overweight (non-insulin dependent diabetes mellitus (type 2) or dyslipoproteinemia).

Contraindications

• Serious eating disorders (bulimia nervosa and anorexia nervosa);
• Obesity of organic origin (for example, due to hypothyroidism);
• Generalized tics (Gilles de la Tourette's syndrome);
• Mental illness;
• Thyrotoxicosis;
• Pheochromocytoma;
• Established alcohol, drug or drug addiction;
• Benign prostatic hyperplasia;
• Closed-angle glaucoma;
• Severe liver / kidney dysfunction;
• Uncontrolled arterial hypertension (blood pressure above 145/90 mm Hg);
• Arrhythmias, tachycardia, occlusive diseases of peripheral arteries, congenital heart defects, decompensated chronic heart failure, coronary heart disease, cerebrovascular diseases (transient cerebrovascular accident, stroke);
• Pregnancy and lactation period;
• Age under 18 and over 65;
• Simultaneous use of other centrally acting agents for weight loss;
• Combined use with drugs containing tryptophan, used for sleep disorders;
• The simultaneous use of monoamine oxidase inhibitors (for example, ephedrine, fenfluramine, ethylamphetamine, dexfenfluramine or phentermine) and within 2 weeks after their withdrawal;
• The simultaneous use of other drugs that have an effect on the central nervous system (for example, antipsychotics or antidepressants);
• Hypersensitivity to the components of Reduksin.

Carefully:

• Arterial hypertension (controlled and in history);
• A history of arrhythmias;
• Chronic circulatory failure;
• Neurological disorders, including seizures and mental retardation (including a history);
• History of motor and verbal tics;
• Diseases of the coronary arteries (including history);
• Mild to moderate renal and / or liver dysfunctions;
• Cholelithiasis.

Instructions for the use of Reduksin: method and dosage

Reduxin should be taken orally once a day, in the morning, swallowing the capsules whole and drinking them with a sufficient amount of liquid, on an empty stomach or during meals.

The recommended starting dose is 10 mg. If within 4 weeks it is not possible to achieve a decrease in body weight by at least 5%, the daily dose is increased to 15 mg.

The total duration of treatment should not exceed 2 years (due to the lack of data on the safety and effectiveness of longer use of sibutramine).

If within 3 months there is no decrease in body weight by at least 5% of the original weight, Reduxin is canceled. You should not continue treatment if, with further administration of the drug, the patient again gains 3 kg or more in weight.

Side effects

• From the side of the central and peripheral nervous system: often (> 10%) - insomnia, dry mouth; sometimes (1-10%) - headache, anxiety, dizziness, paresthesia, changes in taste; rarely (<1%) - back pain, convulsions, irritability, emotional lability, anxiety, depression, nervousness, drowsiness; one patient with schizoaffective disorder, which presumably already existed before taking Reduxin, developed acute psychosis after treatment;
• From the digestive system: often - constipation, loss of appetite; sometimes - exacerbation of hemorrhoids, nausea; rarely - a paradoxical increase in appetite, abdominal pain, a transient increase in the activity of liver enzymes;
• From the side of the cardiovascular system: sometimes - tachycardia, vasodilation, palpitations, moderate rise in blood pressure (BP) at rest by 1-3 mm Hg, moderate increase in heart rate by 3-7 beats / minute; rarely - more pronounced increases in blood pressure and heart rate (heart rate);
• Dermatological reactions: sometimes sweating; rarely - itching of the skin, purpura Shenlein-Henoch (hemorrhage in the skin);
• On the part of the body as a whole: rarely - dysmenorrhea, thrombocytopenia, thirst, flu-like syndrome, rhinitis, bleeding, edema, acute interstitial nephritis.

In rare cases, after the abolition of Reduxin, increased appetite and headache appear.

Side effects usually occur in the first 4 weeks of treatment and are reversible and moderate, with time their severity and frequency decrease.

Overdose

At the moment, there is extremely limited information regarding sibutramine overdose. It is most often manifested by the following undesirable symptoms: dizziness, headache, increased blood pressure, tachycardia. If you suspect an overdose, you should immediately contact your doctor.

Special treatment for an overdose of Reduxin is not carried out, and there is no specific antidote. It is recommended to resort to general measures, which include monitoring the cardiovascular system, ensuring free breathing, and, if necessary, the appointment of supportive symptomatic therapy. Timely intake of activated charcoal, as well as gastric lavage, can reduce the intake of sibutramine into the body. Patients with high blood pressure and tachycardia are allowed to prescribe beta-blockers. The effectiveness of hemodialysis or forced diuresis has not been proven.

special instructions

Reduksin is prescribed only in cases where all non-drug methods of weight loss have proved to be ineffective, i.e. within 3 months, body weight has decreased by less than 5 kg.

Treatment should be supervised by a physician with practical experience in the treatment of obesity. Reception of Reduksin should be combined with dietary food and exercise. An important component of successful therapy is the creation of prerequisites for a persistent change in the patient's lifestyle and dietary habits, which is extremely necessary to maintain the achieved result, including after the end of drug treatment. Patients should understand that non-observance of these requirements will inevitably lead to a repeated increase in body weight and the need to consult a doctor.

Women of childbearing age need to use reliable contraceptives during treatment.

Patients prone to constipation in the first days of treatment need to control the evacuation function of the intestine. In case of constipation, Reduxin is canceled and laxatives are prescribed.

During treatment, it is necessary to periodically measure blood pressure and heart rate: for the first 2 months - every 2 weeks, then - once a month. More careful and frequent monitoring is required in patients with arterial hypertension (blood pressure above 145/90 mm Hg during antihypertensive therapy). Patients whose blood pressure on repeated measurements twice exceeded the indicator of 145/90 mm Hg, treatment with Reduxin is suspended.

The relationship between the use of Reduxin and the development of primary pulmonary hypertension has not been reliably established, however, due to the well-known risk of drugs in this group, with regular medical examinations, special attention should be paid to the presence of symptoms such as swelling in the legs, chest pain, respiratory failure (progressive dyspnea).

Reduksin can affect the ability to concentrate and the speed of reactions; this should be taken into account by vehicle drivers and patients employed in potentially hazardous industries.

With the simultaneous administration of ethanol, an increase in its negative effect was not noted. However, the use of alcohol is absolutely not combined with the dietary measures recommended during the period of treatment with Reduxin.

Drug interactions

Special attention should be paid to the simultaneous administration of drugs that can increase the QT interval, such as some antiarrhythmic drugs (amiodarone, flecainide, quinidine, propafenone, mexiletine, sotalol), histamine H ₁ receptor blockers (terfenadine, astemizole) and stimulants of gastrointestinal motility (tricyclic antidepressants, pimozide, cisapride, sertindole). In addition, caution should be observed in patients who take Reduxin while they have conditions that are risk factors for an increase in the QT interval (for example, hypomagnesemia or hypokalemia).

There should be at least a 2-week interval between taking Reduksin and monoamine oxidase inhibitors.

Inhibitors of microsomal oxidation, including inhibitors of the isoenzyme 3A4 of cytochrome P ₄₅₀ (including cyclosporine, erythromycin, ketoconazole) increase the concentration of sibutramine metabolites in blood plasma, increase heart rate and clinically insignificantly increase the QT interval.

Macrolide antibiotics, phenobarbital, phenytoin, rifampicin, dexamethasone, and carbamazepine can accelerate the metabolism of sibutramine.

The simultaneous use of several drugs that increase the level of serotonin in the blood can lead to serious consequences of such drug interactions.

There are rare cases of the development of serotonin syndrome with the combined use of sibutramine with antitussive drugs (for example, dextromethorphan), potent analgesics (pethidine, pentazocine, fentanyl), selective serotonin reuptake inhibitors (antidepressant drugs), some drugs for the treatment of migraine

Sibutramine has no effect on oral contraceptives.

Analogs

Reduksin's analogs are: Lindaxa, Meridia, Reduxin Met, Slimia, Gold Line.

Terms and conditions of storage

Store at a temperature not exceeding 25 ° C in a dry place out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Reduksin

According to reviews, Reduxin 15 mg is effective when used for weight loss in combination with an active lifestyle. Sometimes patients who write on thematic forums even leave reviews with photos proving the effectiveness of the drug. Often there are positive opinions about Reduksin with a dosage of 10 mg. Those who lost weight on the drug report that their appetite has decreased significantly. This ultimately led to a decrease in body weight.

Some women report that in the first weeks after starting treatment, they suffered from increased thirst. Some of them combined Reduxin with other drugs for weight loss, while they emphasize that this should be done only under the supervision of a doctor. There are a few reviews of doctors about adverse reactions, where it is mentioned that such effects are mild and quickly disappear. In this case, the drug must be taken strictly according to the instructions and not exceed the recommended doses. Sometimes even a daily dose of 20 mg can cause an increase in blood pressure. Doctors also do not recommend drinking alcohol during therapy.

Some reviews mention the program of Elena Malysheva, within the framework of which the group "Lose Weight with Reduksin" was organized. The presenter claims that her participants got rid of the extra 15-20 kg, and many spoke positively about the drug.

Price for Reduksin in pharmacies

The price for Reduxin with a dosage of 10 mg is about 811 rubles (for 10 capsules), 1645-2185 rubles (for 30 capsules), 2787-3172 rubles (for 60 capsules) or 3950-4297 rubles (for 90 capsules). You can buy Reduxin 15 mg for 2500-3075 rubles (for 30 capsules), 4377-4940 rubles (for 60 capsules) or 5611-6690 rubles (for 90 capsules).

Reduksin: prices in online pharmacies

Drug name Price Pharmacy

Reduksin Light capsules 625 mg 30 pcs. 1108 RUB Buy

Reduksin 10 mg + 158.5 mg hard gelatin capsules 30 pcs. 1366 RUB Buy

Reduksin Light capsules 625 mg 90 pcs. 1539 RUB Buy

Reduksin Light Strengthened capsule formula 650 mg 30 pcs. 1724 RUB Buy

Reduxin forte 850mg + 10mg film-coated tablets 30 pcs. 1779 RUB Buy

Reduksin capsules 10mg 30 pcs. RUB 1808 Buy

Reduxin Met table. 850 mg + capsules (10 mg + 158.5) mg tablets and capsules set of 90 pcs. 1988 RUB Buy

Reviews Reduxin Met 1988 RUB Buy

Reduksin 15 mg hard gelatin capsules 30 pcs. 2089 RUB Buy

Reduxin forte tablets p.o.p 850mg + 10mg 30pcs RUB 2160 Buy

Reduksin 10 mg hard gelatin capsules 60 pcs. RUB 2304 Buy

Reduxin Met table. 850 mg + caps. (15 mg + 153.5) mg tablets and capsules set of 90 pcs. 2464 RUB Buy

Reviews Reduxin Met 2464 RUB Buy

Reduksin capsules 15mg 30 pcs. 2526 RUB Buy

Reduxin forte 850mg + 15mg film-coated tablets 30 pcs. 2617 RUB Buy

Reduksin 10 mg + 158.5 mg hard gelatin capsules 90 pcs. 2782 RUB Buy

Reduksin Light Strengthened capsule formula 650 mg 60 pcs. 2811 RUB Buy

Reduksin capsules 10mg 60 pcs. 2844 RUB Buy

Reduksin MET capsules 10mg + 158.5mg No. 30 tablets 850mg 60 pcs. RUB 3148 Buy

Reduksin forte tablets p.o.p 850mg + 15mg 30pcs 3515 RUB Buy

Reduksin 15 mg hard gelatin capsules 60 pcs. RUB 4004 Buy

Reduksin capsules 10mg 90 pcs. RUB 4128 Buy

Reduksin capsules 15mg 60 pcs. 4452 RUB Buy

Reduksin MET capsules 15mg + 153.5mg No. 30 tablets 850mg 60 pcs. RUB 4798 Buy

Reduksin 15 mg + 153.5 mg hard gelatin capsules 90 pcs. RUB 4966 Buy

Reduksin capsules 15mg 90 pcs. 5575 RUB Buy

See all offers from pharmacies

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!